Pacific Point Laboratories, INC.

Pacific Point Laboratories, INC. was paid $38.82M by Medicaid between Jan 2018 and Nov 2024, across 362 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 21% of everything it billed.

33Billing provider infoPACIFIC POINT LABORATORIES, INC.
SAN LUIS OBISPO, CA 93401

33aNPI1457341851assigned 10/26/2005

33bProvider typeClinical Medical Laboratory

28Total paid$38.82M

24GClaims3,699,200

24DCodes billed362

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#27 of 561

Median peer was paid$222K

This provider vs. median175×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	420,971	$4.16M
2019	529,955	$3.32M
2020	605,837	$8.53M
2021	689,057	$8.25M
2022	630,275	$6.63M
2023	674,140	$6.25M
2024incomplete	148,965	$1.69M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	21%	119,298	110,880	$8.11M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	5.5%	129,141	127,346	$2.12M
86003		4.8%	18,954	17,321	$1.88M
80053	Comprehensive metabolic panel	4.7%	275,501	263,906	$1.84M
84443	Thyroid stimulating hormone (TSH)	4.3%	179,467	176,805	$1.67M
80061	Lipid panel	3.9%	222,913	220,391	$1.50M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	3.4%	308,688	290,858	$1.33M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	3.2%	63,034	61,426	$1.26M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.7%	61,921	60,383	$1.06M
83036	Hemoglobin; glycosylated (A1C)	2.6%	208,164	205,257	$1.03M
80050	General health panel	2.1%	33,540	32,974	$830K
86480		1.6%	20,470	20,300	$634K

350 more codes

86235		1.6%	10,827	$624K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.5%	33,881	$564K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.4%	16,098	$532K
84439		1.3%	94,854	$518K
80074		1.3%	21,077	$491K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.2%	43,954	$462K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	17,860	$371K
36415	Collection of venous blood by venipuncture	<1%	100,436	$364K
82607		<1%	49,539	$363K
87086	Culture, bacterial; quantitative colony count, urine	<1%	71,737	$336K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	24,202	$328K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	2,006	$251K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	11,232	$229K
80081		<1%	4,680	$228K
82746		<1%	25,503	$215K
86038		<1%	30,626	$215K
84403		<1%	14,270	$210K
87522	Neg quan hep c or qual rna	<1%	8,075	$189K
84481		<1%	17,043	$186K
84153		<1%	19,934	$186K
83970		<1%	8,756	$183K
86803		<1%	26,278	$180K
86331		<1%	21,226	$174K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	11,037	$171K
82043		<1%	57,079	$167K
84480		<1%	16,605	$163K
83516		<1%	10,030	$141K
81001		<1%	80,850	$140K
82728		<1%	20,632	$140K
87536		<1%	3,572	$137K
80048	Basic metabolic panel (calcium, ionized)	<1%	28,340	$137K
86147		<1%	3,746	$134K
83735		<1%	30,064	$132K
86140		<1%	42,111	$131K
87481		<1%	5,953	$129K
86160		<1%	9,611	$127K
83540		<1%	32,671	$123K
82670		<1%	6,947	$120K
83550		<1%	26,614	$120K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	3,929	$118K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,700	$117K
83880		<1%	6,632	$110K
86376		<1%	13,243	$109K
87186		<1%	21,903	$106K
82274		<1%	13,404	$106K
86592		<1%	38,740	$106K
81514		<1%	742	$104K
82785		<1%	8,101	$101K
86769		<1%	2,933	$99K
83655		<1%	14,128	$99K
87077		<1%	21,122	$97K
84270		<1%	8,297	$95K
87340		<1%	16,205	$94K
80076		<1%	21,437	$93K
82652		<1%	3,927	$91K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,448	$88K
85652		<1%	53,011	$88K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	1,020	$88K
86225		<1%	10,982	$81K
82105		<1%	5,359	$77K
86696		<1%	7,345	$76K
82570		<1%	33,264	$74K
85730		<1%	19,904	$74K
87070		<1%	12,204	$73K
86706		<1%	12,563	$73K
86431		<1%	21,172	$71K
86780		<1%	11,166	$69K
84550		<1%	24,754	$67K
83690		<1%	14,201	$66K
85610		<1%	26,232	$62K
84100		<1%	20,139	$61K
86635		<1%	6,706	$58K
82784		<1%	6,825	$55K
83001		<1%	6,753	$53K
86762		<1%	7,379	$53K
86039		<1%	8,214	$52K
86695		<1%	7,278	$52K
86665		<1%	2,428	$50K
84436		<1%	14,383	$49K
81003		<1%	28,448	$49K
82977		<1%	9,930	$48K
83013		<1%	2,723	$48K
87902		<1%	559	$47K
84144		<1%	3,722	$47K
82248		<1%	18,001	$46K
84425		<1%	3,259	$44K
84702		<1%	6,440	$44K
82950		<1%	13,754	$43K
87493		<1%	2,067	$42K
83002		<1%	5,595	$42K
84154		<1%	4,225	$40K
84445		<1%	1,136	$39K
86800		<1%	4,166	$39K
87209		<1%	3,714	$39K
83993		<1%	2,709	$39K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	2,508	$39K
86787		<1%	4,941	$38K
86694		<1%	5,395	$38K
87653		<1%	2,496	$38K
86200		<1%	8,262	$37K
82627		<1%	2,808	$36K
84146		<1%	4,572	$34K
84681		<1%	2,662	$33K
85027		<1%	11,646	$32K
86704		<1%	5,998	$32K
84207		<1%	1,555	$31K
80069		<1%	5,952	$28K
87075		<1%	5,000	$27K
82550		<1%	7,953	$27K
82103		<1%	2,837	$27K
82140		<1%	2,763	$27K
80164		<1%	3,726	$27K
86812		<1%	1,444	$26K
83520		<1%	3,150	$25K
82378		<1%	3,195	$25K
87899		<1%	4,712	$25K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	84	$24K
85045		<1%	8,018	$23K
87480		<1%	1,741	$23K
86341		<1%	1,242	$23K
88142		<1%	2,169	$23K
87799		<1%	1,379	$22K
86171		<1%	3,379	$22K
82533		<1%	2,257	$22K
87081		<1%	4,883	$21K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	645	$21K
83721		<1%	5,609	$21K
87177		<1%	3,720	$20K
86850		<1%	9,091	$20K
86708		<1%	4,234	$20K
86141		<1%	3,763	$19K
86334		<1%	1,502	$18K
84156		<1%	9,007	$18K
86256		<1%	2,256	$18K
82150		<1%	5,053	$18K
83630		<1%	1,280	$17K
86301		<1%	1,653	$17K
86300		<1%	1,708	$17K
88304		<1%	2,028	$17K
82247		<1%	4,757	$16K
84165		<1%	2,873	$16K
87510		<1%	1,740	$16K
87147		<1%	5,601	$15K
84479		<1%	5,828	$15K
80177		<1%	2,094	$15K
87529		<1%	340	$14K
82024		<1%	630	$14K
87205		<1%	5,787	$14K
86360		<1%	603	$14K
86255		<1%	1,744	$14K
83525		<1%	1,979	$14K
82951		<1%	1,742	$13K
88342		<1%	1,025	$13K
80197		<1%	2,083	$13K
88112		<1%	620	$13K
82947		<1%	5,229	$12K
83615		<1%	3,742	$12K
87660		<1%	1,532	$12K
82390		<1%	1,655	$12K
86901		<1%	8,184	$12K
84432		<1%	1,210	$12K
82172		<1%	1,391	$12K
83498		<1%	809	$12K
84305		<1%	948	$11K
82565		<1%	3,728	$11K
88141		<1%	1,716	$11K
80202		<1%	1,193	$11K
86900		<1%	7,384	$11K
86738		<1%	629	$11K
84466		<1%	1,412	$10K
86703		<1%	941	$10K
84134		<1%	1,135	$10K
82671		<1%	566	$10K
83020		<1%	1,351	$10K
83090		<1%	1,135	$10K
87015		<1%	1,878	$9K
84630		<1%	1,148	$9K
86735		<1%	1,599	$9K
87512		<1%	776	$9K
86361		<1%	735	$9K
81025		<1%	2,806	$8K
86765		<1%	1,638	$8K
85246		<1%	577	$8K
85245		<1%	570	$8K
86664		<1%	815	$8K
80055		<1%	325	$8K
83883		<1%	1,022	$7K
83695		<1%	883	$7K
86663		<1%	831	$7K
85240		<1%	640	$7K
87631		<1%	285	$7K
82465		<1%	2,558	$7K
87046		<1%	3,231	$7K
80178		<1%	1,698	$7K
87807		<1%	825	$7K
86337		<1%	402	$6K
84520		<1%	2,884	$6K
85007		<1%	4,817	$6K
85018		<1%	3,768	$6K
85651		<1%	3,254	$6K
87338		<1%	2,483	$6K
84460		<1%	3,410	$6K
82397		<1%	568	$6K
82330		<1%	730	$6K
84478		<1%	1,374	$5K
87563		<1%	201	$5K
82525		<1%	599	$5K
82310		<1%	1,610	$5K
86304		<1%	1,016	$5K
82164		<1%	449	$5K
85613		<1%	413	$5K
87511		<1%	831	$5K
87797		<1%	205	$4K
80159		<1%	549	$4K
82985		<1%	414	$4K
84450		<1%	3,009	$4K
86644		<1%	547	$4K
87517		<1%	274	$4K
86709		<1%	872	$4K
88312		<1%	184	$4K
80175		<1%	506	$4K
82952		<1%	2,209	$4K
84703		<1%	1,887	$4K
83986		<1%	1,242	$4K
82088		<1%	149	$4K
86593		<1%	1,928	$4K
86146		<1%	136	$4K
84482		<1%	304	$4K
84446		<1%	365	$4K
85379		<1%	666	$3K
86645		<1%	381	$3K
80156		<1%	545	$3K
84484		<1%	524	$3K
86705		<1%	400	$3K
84376		<1%	710	$3K
87497		<1%	198	$3K
82626		<1%	161	$3K
84155		<1%	1,662	$3K
87210		<1%	839	$3K
86308		<1%	693	$2K
86359		<1%	206	$2K
84166		<1%	203	$2K
85598		<1%	194	$2K
87581		<1%	84	$2K
87486		<1%	84	$2K
80354		<1%	278	$2K
80051		<1%	359	$2K
84132		<1%	774	$2K
87088		<1%	324	$2K
82040		<1%	657	$2K
86060		<1%	441	$2K
85014		<1%	1,348	$2K
84244		<1%	128	$2K
83014		<1%	432	$2K
82668		<1%	211	$2K
86701		<1%	2,132	$2K
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	106	$2K
82705		<1%	456	$2K
80324		<1%	614	$2K
P9011	Blood, split unit	<1%	672	$2K
88341		<1%	17	$2K
85525		<1%	181	$2K
86702		<1%	2,125	$2K
80185		<1%	202	$1K
84590		<1%	161	$1K
80348		<1%	651	$1K
87106		<1%	157	$1K
83010		<1%	142	$1K
85635		<1%	181	$1K
87040		<1%	148	$1K
85049		<1%	681	$1K
87076		<1%	158	$1K
83921		<1%	187	$1K
80299		<1%	111	$1K
87428		<1%	17	$998.27
80183		<1%	107	$997.80
82157		<1%	59	$970.36
85041		<1%	473	$825.49
85670		<1%	210	$791.48
82239		<1%	60	$764.33
84066		<1%	110	$688.81
85732		<1%	154	$666.61
82681		<1%	45	$641.49
84560		<1%	134	$615.24
87449		<1%	80	$603.31
85048		<1%	459	$592.99
80358		<1%	629	$566.54
80349		<1%	696	$559.66
82340		<1%	143	$556.47
85380		<1%	142	$511.48
84295		<1%	221	$504.05
87184		<1%	66	$503.16
86355		<1%	53	$493.10
86008		<1%	13	$412.22
86788		<1%	22	$403.48
87280		<1%	52	$388.96
83704		<1%	12	$373.92
86357		<1%	54	$364.21
82085		<1%	81	$363.47
82608		<1%	32	$353.50
86671		<1%	26	$352.20
86789		<1%	22	$344.52
88300		<1%	12	$339.92
84075		<1%	145	$335.43
83605		<1%	54	$323.07
82747		<1%	44	$317.68
80346		<1%	645	$309.60
87260		<1%	32	$292.90
87299		<1%	32	$292.90
87279		<1%	32	$292.90
86677		<1%	75	$284.90
81015		<1%	180	$279.05
87252		<1%	12	$255.48
87328		<1%	25	$252.50
87329		<1%	25	$252.50
84402		<1%	13	$246.36
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	182	$245.26
82104		<1%	25	$244.10
86713		<1%	14	$241.76
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	26	$212.28
86356		<1%	16	$208.76
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	44	$185.76
87102		<1%	41	$179.98
82553		<1%	36	$176.18
87276		<1%	32	$173.13
87275		<1%	32	$171.97
86001		<1%	47	$157.20
86727		<1%	24	$154.49
83519		<1%	13	$147.24
80353		<1%	618	$123.60
86335		<1%	12	$109.99
81329		<1%	49	$109.60
83835		<1%	14	$108.40
80361		<1%	677	$105.05
82365		<1%	12	$100.99
80165		<1%	12	$95.96
80359		<1%	137	$87.50
87185		<1%	90	$86.44
80345		<1%	617	$74.10
85060		<1%	12	$63.41
82270		<1%	93	$33.89
80373		<1%	423	$21.39
80369		<1%	462	$20.33
80365		<1%	134	$17.50
86777		<1%	49	$14.61
86778		<1%	47	$12.80
85008		<1%	14	$7.28
87254		<1%	15	$5.41
80321		0%	376	$0.00
36416		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialROBERTS, CORY (PRESIDENT)

Same official

Other billing entities under ROBERTS, CORY

Full network →

Provider	Location	Paid
Propath Associates, PLLC	Dallas, TX	$542K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.